Xencor to Present at the Barclays Global Healthcare Conference

Rhea-AI Summary

Xencor, Inc. (NASDAQ:XNCR) announced that its CEO, Bassil Dahiyat, Ph.D., will participate in a virtual fireside chat at the Barclays Global Healthcare Conference on March 10, 2021, at 2:25 p.m. ET. A live webcast will be available on the company's website, with a replay accessible for 30 days afterward. Xencor focuses on developing engineered monoclonal antibodies and cytokines for treating cancer and autoimmune diseases, with 20 candidates currently in clinical development utilizing its XmAb® antibody engineering technology.

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will participate in a virtual fireside chat at the Barclays Global Healthcare Conference on Wednesday, March 10, 2021 at 2:25 p.m. ET / 11:25 p.m. PT.

A live webcast will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com. Following the webcast, a replay will be archived on the website for at least 30 days.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 20 candidates engineered with Xencor's XmAb^® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of proteins resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210303005914/en/

FAQ

When is Xencor's virtual fireside chat at the Barclays Global Healthcare Conference?

Xencor's virtual fireside chat is scheduled for March 10, 2021, at 2:25 p.m. ET.

How can I access the webcast of Xencor's fireside chat?

The webcast can be accessed under 'Events & Presentations' in the Investors section of Xencor's website.

What is Xencor developing?

Xencor is developing engineered monoclonal antibodies and cytokines for cancer and autoimmune disease treatment.

How many candidates is Xencor developing?

Xencor is developing 20 candidates in clinical development using its XmAb® technology.

Where can I find more information about Xencor?

More information about Xencor can be found on their official website at www.xencor.com.